top of page

ABOUT US

Combining multidisciplinary basic, translational and clinical approaches for cancer therapy

In our lab, we invest multidisciplinary efforts to elucidate the basic molecular mechanisms responsible for cancer progression to an aggressive, metastatic, drug-resistant phenotype in order to reveal new “druggable targets” for clinical translation. To achieve this goal, we exploit a rich platform of cell lines, ex vivo 3D models and in vivo mouse models of cancer as well as fresh and archived tissue specimens obtained from fruitful collaborations with several of TAU’s affiliated hospitals. We use a range of molecular and functional techniques to identify and validate new markers and drivers of cancer progression. The newly-gained knowledge is harnessed for the design of novel clinically-relevant polymer-based diagnostic and therapeutic tools for cancer. Our vision is that our multidisciplinary approach will revolutionize our perception of tumor progression and consequently the way we diagnose and treat cancer.

Ronit_Lady-Globes_1_edited_edited.jpg

Photo by: Eric Sultan (Lady Globes)

Ronit Satchi-Fainaro, Ph.D.

Head, Cancer Research and Nanomedicine Laboratory

Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies

Head of the TAU Kahn 3D Printing Initiative

Spheres-c.png

THE FUTURE IS HERE

Watch the Satchi-Fainaro Lab on Ben-Shani's show, Kan 11

RESEARCH HIGHLIGHTS

Our new paper on the role of MCP-1/CCR2 axis in melanoma brain metastases is out

JOIN OUR TEAM!

Our lab is seeking for highly motivated and talented postdocs with background in cancer biology, chemistry or chemical engineering

bottom of page